Great result! Amazing thing is that probably no US sales from April, May or June are included in these cash figures due to US payment terms but they will show up in the year end results in a few weeks. Really amazing EPS growth to come in the year end reports. Global pandemic and all, great stuff no other comparable biotech is putting out growth figures anything like this. Undervalued.
All IMO DYOR
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.30 |
Change
0.000(0.00%) |
Mkt cap ! $716.1M | |||
| Open | High | Low | Value | Volume |
| $14.21 | $14.33 | $13.69 | $2.607M | 186.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 658 | $14.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.32 | 698 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |